Animal models of antiretroviral prophylaxis for HIV prevention

Current Opinion in HIV and AIDS

Volumn 7, Issue 6, 2012, Pages 505-513

  García Lerma, J Gerardo ^a   Heneine, Walid ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

emtricitabine; macaque models; microbicides; preexposure prophylaxis; tenofovir

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DAPIVIRINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MARAVIROC; MC 1220; MEDROXYPROGESTERONE ACETATE; MIV 150; N [3 [4 (3 BENZYL 1 ETHYL 5 PYRAZOLYL) 1 PIPERIDINYLMETHYL] 4 (3 FLUOROPHENYL)CYCLOPENTYL] N METHYLVALINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; TENOFOVIR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIVIRAL RESISTANCE; CHLAMYDIA TRACHOMATIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG TISSUE LEVEL; HIGH RISK POPULATION; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MACACA; MALE HOMOSEXUAL; MULTIPLE CYCLE TREATMENT; NONHUMAN; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; RECTUM MUCOSA; REVIEW; SEXUAL TRANSMISSION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRICHOMONAS VAGINALIS; VAGINA MUCOSA; VIRUS ENTRY; VIRUS REPLICATION; VIRUS TRANSMISSION; WILD TYPE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-HIV AGENTS; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; HIV; HIV INFECTIONS; HUMANS; MACACA; MICE; MICE, SCID; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME;

EID: 84868508717     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328358e484     Document Type: Review

References (60)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, et al., the TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434; doi: 10.1056/NEJMoa 1110711.
3. Baeten JM, Donnell D, Ndase P, et al., Team tPPS. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410; doi: 10.1056/NEJMoa1108524.
4. Van Damme L, Corneli A, Ahmed K, et al. Group tF-PS. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422; doi: 10.1056/NEJMoa1202614.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al., on behalf of the CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
6. Hayes R, Watson-Jones D, Celum C, et al. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS 2010; 24 (Suppl 4):S15-S26.
7. Haase A. Perils at the mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005; 5:783-792.
8. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74:6087-6095.
9. Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458:1034-1038.
10. Miller CJ, Li Q, Abel K, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79:9217-9227.
11. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011; 62:127-139.
12. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270:1197-1199.
13. van Rompay KK, Berardi CJ, Aguirre NL, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 1998; 12:F79-83.
14. van Rompay KK, Schmidt KA, Lawson JR, et al. Topical administration of lowdose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus. J Infect Dis 2002; 186:1508-1513.
15. Van Rompay KK, Kearney BP, Sexton JJ, et al. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr 2006; 43:6-14.
16. Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006; 194:904-911.
17. Denton PW, Estes JD, Sun Z, et al. Antiretroviral preexposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5:e16.
18. García-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28.
19. García-Lerma JG, Cong M, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques form rectal SHIV infection. Sci Transl Med 2010; 2:14ra14.
20. Denton PW, Krisko JF, Powell DA, et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 2010; 5:e8829.
21. Cong M, Youngpairoj AS, Zheng Q, et al. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J Virol 2011; 85:7933-7936.
22. Cranage M, Sharpe S, Herrera C, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local preexposure application of tenofovir gel. PLoS Med 2008; 5:e157.
23. Parikh U, Dobard C, Sharma S, et al. Complete protection from repeated vaginal SHIV exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009; 83:10358-10365.
24. Denton PW, Othieno F, Martinez-Torres F, et al. One percentage tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 2011; 85:7582-7593.
25. Dobard C, Sharma S, Martin A, et al. Durable protection from vaginal simianhuman immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 2012; 86:718-725.
26. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-4273.
27. Kim C, Adams D, Bashirian S, et al. Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV preclinical interventions in nonhuman primates. J Med Primatol 2006; 35:210-216.
28. Otten RA, Adams DR, Kim CN, et al. Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis 2005; 19:164- 173.
29. Eisenberg EJ, He GX, Lee WA. Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMAPA, in blood. Nucleosides, Nucleotides Nucleic Acids 2001; 20:1091-1098.
30. Lee WA, He G, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrobial Agents Chemother 2005; 49:1898- 1906.
31. García-Lerma JG, Aung W, Cong ME, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol 2011; 85:6610-6617.
32. Blakley GB, Beamer TW, Dukelow WR. Characteristics of the menstrual cycle in nonhuman primates. IV. Timed mating in Macaca nemestrina. Lab Anim 1981; 15:351-353.
33. Sodora DL, Gettie A, Miller CJ, Marx PA. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retroviruses 1998; 14 (Suppl 1):S119-S123.
34. Vishwanathan SA, Guenthner PC, Lin CY, et al. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011; 57:261-264.
35. Wira CR, Fahey JV. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008; 22:1909-1917.
36. Radzio J, Aung W, Ruone S, et al. Intermittent oral PrEP with Truvada prevents vaginal SHIV transmission in macaques. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 2012; Seattle, WA; abstract 1086.
37. Network HPT. HPTN 067, The ADAPT Study: A Phase II, Randomized, Open- Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) In. http://www.hptn.org/research-studies/hptn067.asp: HIV Prevention Trials Network (HPTN) and Family Health International (FHI); 2012.
38. Neff CP, Ndolo T, Tandon A, et al. Oral preexposure prophylaxis by antiretrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010; 21:e15257.
39. Henning T, Fakile Y, Phillips C, et al. Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3). J Med Primatol 2011; 40:214-223.
40. Heffron R, Donnell D, Rees H, et al., for the Partners in Prevention HSV/HIV Transmission Study Team. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
41. Hild-Petito S, Veazey RS, Larner JM, et al. Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II, on the vaginal epithelium of rhesus monkeys. AIDS Res Hum Retroviruses 1998; 14 (Suppl 1):S125-S130.
42. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2:1084-1089.
43. Abel K, Rourke T, Lu D, et al. Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239. J Infect Dis 2004; 190:1697-1705.
44. Mauck CK, Callahan MM, Baker J, et al. The effect of one injection of Depo- Provera on the human vaginal epithelium and cervical ectopy. Contraception 1999; 60:15-24.
45. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012; 14:17-27.
46. Pingen M, Nijhuis M, de Bruijn JA, et al. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 2011; 66:1467-1480.
47. van Rompay KK, Miller MD, Marthas ML, et al. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 2000; 74:1767-1774.
48. Cong M, Youngpairoj AS, Aung WS, et al. Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162p3 mutants in macaques. Virology 2011; 412:435-440.
49. Curtis KA, Kennedy MS, Luckay A, et al. Delayed maturation of antibody avidity but not seroconversion in Rhesus macaques infected with SHIV during oral preexposure prophylaxis. J Acquir Immune Defic Syndr 2011; 57:355- 362.
50. Kersh EN, Luo W, Zheng Q, et al. Reduced inflammation and CD4 loss in acute SHIV infection during oral PrEP. J Infect Dis 2012; 206:770-779; doi: 10.1093/infdis/jis422.
51. Zheng Q, Ruone S, Switzer WM, et al. Limited SHIV env diversification in macaques failing oral antiretroviral preexposure prophylaxis. Retrovirology 2012; 9:40.
52. Shattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med 2012; 2:a007385.
53. Gaertner H, Cerini F, Escola JM, et al. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc Natl Acad Sci U S A 2008; 105:17706-17711.
54. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306:485-487.
55. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438:99-102.
56. Veazey RS, Ketas TJ, Dufour J, et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010; 202:739-744.
57. Nuttall J, Kashuba A, Wang R, et al. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob Agents Chemother 2012; 56:103-109.
58. Caron M, Besson G, Etenna SL, et al. Protective properties of nonnucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV. Virology 2010; 405:225-233.
59. Kenney J, Aravantinou M, Singer R, et al. An antiretroviral/zinc combination gel provides 24 h of complete protection against vaginal SHIV infection in macaques. PLoS One 2011; 6:e15835.
60. Dobard C, Sharma S, Parikh U, et al. High protection against vaginal infection in macaques by PEP with gel containing RAL. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections. Boston